Koliani-Pace Jenna L, Siegel Corey A
Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Dartmouth-Hitchcock, 1 Medical Center Drive, Lebanon, NH 03766, USA.
Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Gastrointest Endosc Clin N Am. 2019 Jul;29(3):395-404. doi: 10.1016/j.giec.2019.02.003. Epub 2019 Apr 5.
Both Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBD) that can lead to progressive irreversible bowel damage. Selecting the most appropriate therapy for patients is a challenge because not all patients diagnosed with IBD have complications, and the amount of time to develop a complication is different for individuals. Models using patient characteristics, genetics, and immune responses help identify those patients who require early aggressive therapy with a goal to modify their disease course. Future research will help identify the role that the microbiome, metagenomics, metaproteomics, and microRNAs play in a patient prognosis.
克罗恩病和溃疡性结肠炎均为炎症性肠病（IBD），可导致进行性不可逆的肠道损伤。为患者选择最合适的治疗方法是一项挑战，因为并非所有诊断为IBD的患者都会出现并发症，而且个体出现并发症的时间也有所不同。利用患者特征、遗传学和免疫反应的模型有助于识别那些需要早期积极治疗以改变疾病进程的患者。未来的研究将有助于确定微生物组、宏基因组学、宏蛋白质组学和微小RNA在患者预后中所起的作用。
